Document Detail


The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer.
MedLine Citation:
PMID:  24649318     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
It has been demonstrated that erlotinib is effective in treating patients with brain metastasis from non-small-cell lung cancer. However, the number of studies determining the erlotinib concentration in these patients is limited. The purpose of this study was to measure the concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung carcinoma. Six patients were treated with the standard recommended daily dose of erlotinib (150 mg) for 4 weeks. All the patients had previously received chemotherapy, but no brain radiotherapy. At the end of the treatment period, blood plasma and cerebrospinal fluid samples were collected and the erlotinib concentration was determined by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The average erlotinib concentration in the blood plasma and the cerebrospinal fluid was 717.7±459.7 and 23.7±13.4 ng/ml, respectively. The blood-brain barrier permeation rate of erlotinib was found to be 4.4±3.2%. In patients with partial response (PR), stable disease (SD) and progressive disease (PD), the average concentrations of erlotinib in the cerebrospinal fluid were 35.5±19.0, 19.1±8.7 and 16.4±5.9 ng/ml, respectively. In addition, the efficacy rate of erlotinib for metastatic brain lesions was 33.3%, increasing to 50% in patients with EGFR mutations. However, erlotinib appeared to be ineffective in cases with wild-type EGFR. In conclusion, a relatively high concentration of erlotinib was detected in the cerebrospinal fluid of patients with brain metastases from non-small-cell lung cancer. Thus, erlotinib may be considered as a treatment option for this patient population.
Authors:
Yanming Deng; Weineng Feng; Jing Wu; Zecheng Chen; Yicong Tang; Hua Zhang; Jianmiao Liang; Haibing Xian; Shunda Zhang
Related Documents :
23521518 - Essential tremor 10, 20, 30, 40: clinical snapshots of the disease by decade of duration.
23453478 - Evaluation of spondylarthritis activity by patients and physicians: asdas, basdai, pass...
24470738 - Significance of extracapillary proliferation in iga-nephropathy patients with regard to...
23676378 - Relationship between eeg beta power abnormality and early diagnosis of cognitive impair...
6983308 - Electronystagmographic findings in idiopathic sudden hearing loss.
7104588 - Natural killer cell activity and response to phytohaemagglutinin compared with the hist...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-9-23
Journal Detail:
Title:  Molecular and clinical oncology     Volume:  2     ISSN:  2049-9450     ISO Abbreviation:  Mol Clin Oncol     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-3-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101613422     Medline TA:  Mol Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  116-120     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinicopathological significance of CD133 in lung cancer: A meta-analysis.
Next Document:  Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-po...